SEPSF (ASEP Medical Holdings) FCF Margin % : -101.82% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ASEP Medical Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ASEP Medical Holdings's Free Cash Flow for the three months ended in Sep. 2024 was $-0.06 Mil. ASEP Medical Holdings's Revenue for the three months ended in Sep. 2024 was $0.06 Mil. Therefore, ASEP Medical Holdings's FCF Margin % for the quarter that ended in Sep. 2024 was -101.82%.

As of today, ASEP Medical Holdings's current FCF Yield % is -29.00%.

The historical rank and industry rank for ASEP Medical Holdings's FCF Margin % or its related term are showing as below:

SEPSF' s FCF Margin % Range Over the Past 10 Years
Min: -12938.1 Med: -12938.1 Max: -459.44
Current: -459.44

During the past 3 years, the highest FCF Margin % of ASEP Medical Holdings was -459.44%. The lowest was -12938.10%. And the median was -12938.10%.

SEPSF's FCF Margin % is ranked worse than
65.26% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs SEPSF: -459.44

ASEP Medical Holdings FCF Margin % Historical Data

The historical data trend for ASEP Medical Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASEP Medical Holdings FCF Margin % Chart

ASEP Medical Holdings Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

-12,656.25

ASEP Medical Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial										-	-3,681.25	-189.09	-144.44	-101.82

Competitive Comparison of ASEP Medical Holdings's FCF Margin %

For the Biotechnology subindustry, ASEP Medical Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASEP Medical Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ASEP Medical Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ASEP Medical Holdings's FCF Margin % falls into.

ASEP Medical Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ASEP Medical Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2.025	/	0.016
	=	-12,656.25 %

ASEP Medical Holdings's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.056	/	0.055
	=	-101.82 %

ASEP Medical Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of ASEP Medical Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ASEP Medical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASEP Medical Holdings Inc (OTCPK:SEPSF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

JJ8:Germany ASEP:Canada

Address

730 View Street, Suite 420, Victoria, BC, CAN, V8W 3Y7

Website

https://www.asepmedical.com

ASEP Medical Holdings Inc is a biotechnology firm pursuing the commercialization of broad-spectrum peptide technology. The Company is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine and is engaged in the business of acquiring research and development assets, technology, or businesses in life sciences and medical diagnostics.